A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer.

Trial Profile

A Phase 1b/2 Study to Assess the Safety and Efficacy of AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Rilotumumab (Primary) ; Mitoxantrone; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Feb 2012 Results presented at the 2012 Genitourinary Cancers Symposium.
    • 08 Sep 2011 Planned end date changed from 1 Mar 2013 to 1 Sep 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top